Corynebacterium Imitans: Traits, Genetics, and Host Interactions

Corynebacterium imitans is a bacterial species first isolated from the throats of patients suspected of having diphtheria, earning its name from the Latin “imitans” (imitating) because it mimics the clinical presentation of diphtheria without actually producing the diphtheria toxin. Identified and formally described in the late 1990s through 16S rRNA gene sequencing, it remains an uncommon but clinically interesting organism. Its significance lies in the diagnostic confusion it can cause and in what it reveals about the broader genus Corynebacterium, a group that includes both harmless skin commensals and dangerous pathogens.

How C. Imitans Was Discovered and Named

The species was formally proposed after researchers isolated coryneform bacteria from patients who showed signs consistent with pharyngeal diphtheria. When the isolates were subjected to detailed biochemical and chemotaxonomic analysis, they turned out to be something new: a bacterium that did not match any previously described Corynebacterium species. Comparative 16S rRNA gene sequence analysis confirmed that it represented a distinct lineage within the genus, and the name Corynebacterium imitans sp. nov. was proposed, with the type strain designated NCTC 13015.¹ The species name was chosen deliberately: clinicians encountering it might initially believe they were dealing with Corynebacterium diphtheriae, the classic agent of diphtheria, when in fact they had stumbled onto an imitator.

One of the original isolates came from a five-month-old boy with suspected pharyngeal diphtheria, underscoring how convincingly C. imitans can present in a clinical setting.² The fact that a healthy infant was the index case hints that C. imitans can colonize the upper respiratory tract of otherwise healthy individuals, much like other non-toxigenic corynebacteria do. Whether C. imitans is an opportunistic pathogen that occasionally causes disease, or a commensal that simply gets caught in the diagnostic net when clinicians are screening for diphtheria, is still not entirely settled. The organism is rare enough that large-scale epidemiological data are essentially nonexistent.

Why It Looks Like Diphtheria but Is Not

The clinical concern with diphtheria is the potent toxin produced by toxigenic strains of C. diphtheriae (and occasionally by C. ulcerans or C. pseudotuberculosis). That toxin can damage the heart, kidneys, and nervous system, making diphtheria a medical emergency. C. imitans sidesteps this danger: when researchers tested the original isolates for the diphtheria toxin gene using PCR and for the toxin protein using the Elek immunoprecipitation test, neither the gene nor its product was detected.¹ The absence of the toxin gene makes a disease association with diphtheria-like tissue damage far less likely.

Still, a laboratory receiving a throat culture from a patient with pharyngeal membrane and finding a Corynebacterium cannot simply wave it off. Diphtheria outbreaks still occur in parts of the world with low vaccine coverage, and any Corynebacterium recovered from a suspected case needs to be carefully identified. The difficulty is that routine culture and staining can make C. imitans look similar to C. diphtheriae: both are Gram-positive, non-motile, club-shaped rods that grow on standard laboratory media. The original investigators found that detailed biochemical and chemotaxonomic profiling could differentiate C. imitans from all other defined Corynebacterium species, but that level of workup goes well beyond what many smaller clinical laboratories can do on a routine basis.

Genomic Features

The complete genome of the type strain, C. imitans DSM 44264, was sequenced and deposited for public access. It spans about 2.57 million base pairs with a mean G+C content of roughly 64%.² Both numbers sit comfortably within the range seen across the genus Corynebacterium, where genome sizes typically run from about 2.4 to 3.1 million base pairs and G+C content hovers in the mid-50s to mid-60s.

Having the full genome in hand opened the door for comparative analysis. Researchers can now look for the presence or absence of known virulence-associated genes, iron uptake systems, adhesion factors, and antibiotic resistance determinants. For C. imitans specifically, the genome confirmed what the phenotypic tests already suggested: the tox gene encoding diphtheria toxin is absent, consistent with the PCR and Elek test results from the original characterization. The genome also provides a reference for future isolates, allowing microbiologists to determine whether newly recovered strains from clinical or environmental samples truly belong to the species or represent something else.

Evolutionary Relatives and the Deep-Sea Connection

One of the more surprising findings to come out of Corynebacterium taxonomy in recent years was the discovery of C. imitans’ closest known phylogenetic neighbor not in a hospital ward but in the hadopelagic zone of the ocean. A bacterium isolated from deep-sea water in the New Britain Trench, eventually named Corynebacterium hadale, showed the highest 16S rRNA gene sequence similarity to C. imitans at about 97.9%. Despite that relatively high genetic similarity at the ribosomal RNA level, the two organisms are clearly distinct species: the digital DNA-DNA hybridization value between them was only about 24.5%, and their average nucleotide identity was around 82%.³

This kind of relationship is a useful reminder that members of the same bacterial genus can occupy radically different ecological niches. C. imitans has been found in the human pharynx; its nearest relative lives in some of the deepest ocean water on the planet. Neither tells you much about the other’s lifestyle, but both share an evolutionary ancestor within the Corynebacterium lineage. For microbiologists, these phylogenetic relationships help build the family tree of the genus and define where one species ends and another begins, a project that is still very much ongoing as new Corynebacterium species continue to be described from diverse environments.

How Laboratories Identify Corynebacterium Species Today

When C. imitans was first described in the late 1990s, identification depended on a laborious combination of biochemical tests, cell-wall lipid analysis, and 16S rRNA gene sequencing. That approach was accurate but slow, and it was only available in reference laboratories. Most clinical labs at the time would report an unidentified Corynebacterium as “diphtheroids” and move on unless diphtheria was specifically suspected.

The landscape has shifted substantially with the adoption of MALDI-TOF mass spectrometry, a technology that identifies bacteria by comparing the mass spectrum of their proteins against a reference database. MALDI-TOF is now available in most large clinical microbiology laboratories and offers rapid, accurate, and affordable species-level identification for many Corynebacterium species.⁴ The technology works well when the reference database includes the species in question, which is a potential weak point for uncommon organisms like C. imitans. If the database does not have a robust entry for a particular species, MALDI-TOF can misidentify it or return a low-confidence match. As more genomes and reference spectra are deposited, the accuracy of MALDI-TOF identification for rare Corynebacterium species continues to improve.

Whole-genome sequencing is increasingly accessible as well and serves as the gold standard when MALDI-TOF results are ambiguous. For research purposes, sequencing is indispensable: it reveals not just the identity of the organism but also its resistance genes, virulence determinants, and phylogenetic placement. For a routine clinical lab, however, MALDI-TOF usually provides a fast enough answer to guide treatment decisions.

Antibiotic Susceptibility Across the Genus

Published data on the antibiotic susceptibility of C. imitans specifically are extremely limited, given how rarely it is isolated. What clinicians and microbiologists tend to rely on instead is the broader susceptibility picture for Corynebacterium species as a group, with the understanding that individual species can deviate from the pattern.

A study comparing disk diffusion and agar dilution methods across a range of clinical Corynebacterium isolates found that all tested isolates were susceptible to vancomycin and minocycline. However, a consistent susceptibility pattern to beta-lactam antibiotics was not observed across different species, and almost all isolates showed resistance to macrolides and lincosamides.⁵ That finding matters because macrolides (like erythromycin) are sometimes chosen empirically for upper respiratory infections, and they would be a poor bet against many corynebacteria.

Separately, a study of Corynebacterium isolates from a hospital environment found that some were highly resistant to penicillin, ciprofloxacin, and linezolid, an unusual pattern that differed from other strains of the genus.⁶ Linezolid resistance in Corynebacterium is particularly noteworthy because linezolid is sometimes used as a last-resort agent for multidrug-resistant Gram-positive infections. These findings underscore that antibiotic susceptibility testing on the actual isolate is important whenever a Corynebacterium infection is being treated, rather than relying on assumptions about the genus.

For C. imitans, vancomycin is considered a reasonable empiric choice based on the genus-wide data showing near-universal susceptibility. But without species-specific breakpoints and large datasets, clinicians encountering a confirmed C. imitans infection would be wise to run a full susceptibility panel.

The Broader Diphtheriae Species Complex

C. imitans sits taxonomically near the group sometimes called the Corynebacterium diphtheriae species complex, a cluster of related species that share certain characteristics and clinical relevance. The most medically important members of this complex are C. diphtheriae itself, C. ulcerans, and C. pseudotuberculosis. These three species can carry the tox gene (usually acquired from a bacteriophage) and produce diphtheria toxin. C. imitans, as established, does not carry the gene, but its phylogenetic proximity and its clinical mimicry of diphtheria keep it loosely associated with this group in microbiological discussions.

Understanding the complex matters because it informs surveillance strategies. Public health laboratories that screen for diphtheria need to distinguish toxigenic from non-toxigenic strains and also need to correctly identify which species they are dealing with. A toxin-negative C. imitans isolate recovered from a pharyngeal swab should not trigger the same public health response as a toxin-positive C. diphtheriae isolate, but both require accurate identification to reach that conclusion. The emergence of MALDI-TOF and sequencing has made this easier in well-equipped laboratories, though resource-limited settings may still rely on older methods that are less precise at the species level.

Zoonotic Dimensions of Related Species

While C. imitans has been recovered from human patients, some of its close relatives in the diphtheriae complex have a well-documented animal reservoir. C. ulcerans, in particular, has been isolated from dogs, cats, rats, rabbits, and horses. In a French case series of 64 infections caused by members of the diphtheriae species complex in companion animals, the majority involved dogs and cats, with C. ulcerans frequently recovered from nasal swabs, skin wounds, and ear infections.⁷ The same study flagged C. ulcerans as an important zoonotic risk, meaning it can jump from animals to humans, and identified a newer species, C. rouxii, as a potential novel zoonotic agent.

Transmission from pet to owner has been documented. In one case, a domestic cat was identified as the probable source of a human skin infection caused by toxigenic C. ulcerans. The presence of C. ulcerans in the cat’s mouth was confirmed by 16S rRNA gene analysis, and the case demonstrated that household pets, not just farm livestock, can serve as carriers and infectious sources.⁸

Whether C. imitans itself has an animal reservoir is unknown. It has not been formally reported in companion animals or livestock, but its rarity means it could easily be overlooked. Non-toxigenic corynebacteria recovered from animals are often not identified to the species level, so C. imitans could theoretically circulate undetected. The broader lesson from C. ulcerans research is that the diphtheriae species complex does not respect the boundary between human and veterinary medicine, and surveillance efforts benefit from looking at both sides.

Why C. Imitans Gets Overlooked

There is a structural reason C. imitans remains poorly studied: it is not dangerous enough to demand attention and not common enough to generate large datasets. In clinical microbiology, non-toxigenic corynebacteria recovered from throat cultures are often dismissed as contaminants or normal flora. Unless the laboratory is specifically investigating a suspected diphtheria case, a Corynebacterium isolate may never be identified beyond the genus level. This means C. imitans infections, if they occur, could be flying under the radar. The organism might cause low-grade pharyngitis that resolves on its own, or it might be a true commensal that only shows up because clinicians were looking for C. diphtheriae. Without a systematic effort to identify and track it, we simply do not know.

The medical literature on C. imitans consists largely of the original species description, the genome announcement, and scattered references in review articles about the genus. Compare that with the hundreds of studies on C. diphtheriae or C. ulcerans, and it becomes clear that C. imitans occupies a blind spot. This is not unusual in microbiology. The genus Corynebacterium contains well over 100 recognized species, many described from just a handful of isolates. Researchers who study these organisms sometimes joke that we know more about the bacteria in extreme environments than about the ones living in our own throats.

Practical Implications for Clinicians

If you work in a clinical laboratory or are a physician managing a patient with suspected diphtheria, C. imitans is worth knowing about for one main reason: its presence in a throat culture can trigger unnecessary alarm. A pharyngeal Corynebacterium that tests negative for diphtheria toxin by both PCR and the Elek test is not going to cause the systemic complications of diphtheria, regardless of what the colony morphology looks like on a plate. Confirming species-level identity through MALDI-TOF or sequencing can put the finding in proper clinical context and potentially spare the patient from aggressive treatment or public health contact tracing that would be warranted for toxigenic C. diphtheriae.

At the same time, any Corynebacterium isolate from a clinically significant site deserves a thoughtful look. The genus includes genuine pathogens beyond C. diphtheriae. Some Corynebacterium species cause endocarditis, prosthetic joint infections, and catheter-related bloodstream infections. C. imitans’ clinical significance remains ambiguous, but dismissing it reflexively as a contaminant is a habit that microbiologists are increasingly being urged to reconsider for the genus as a whole. The availability of rapid identification tools means that the cost of checking has dropped dramatically, even if the organism turns out to be harmless most of the time.

Open Questions in C. Imitans Biology

Several basic questions about C. imitans remain unanswered. Its natural ecological niche is unclear: is the human pharynx its primary habitat, or is it found in other body sites or in the environment? Whether it carries any virulence factors besides the absent diphtheria toxin gene has not been thoroughly explored at the functional level. The genome is available, but systematic searches for adhesins, siderophores, and other factors that help bacteria colonize and persist in a host have not been published in detail for this species specifically.

Its geographic distribution is another open question. The original isolates came from Europe, but whether C. imitans circulates in other regions is unknown. Given how rarely it is identified, the apparent geographic restriction could simply reflect where the most thorough laboratory workups have been done. Surveillance studies using modern molecular methods in regions with high diphtheria burden could reveal whether C. imitans is quietly present in those populations, potentially complicating diagnostic algorithms that rely on culture-based identification of diphtheria-like organisms.

Finally, the question of horizontal gene transfer looms. In the world of corynebacteria, the diphtheria toxin gene is carried on a bacteriophage. Theoretically, a non-toxigenic species like C. imitans could acquire this phage and become toxigenic, just as some strains of C. ulcerans have. No such event has been documented for C. imitans, and its genome currently lacks the phage attachment sites that would facilitate tox gene integration, but “currently lacks” and “cannot acquire” are different claims. Monitoring the genomic evolution of rare species like C. imitans is precisely the kind of low-frequency, high-consequence surveillance that public health genomics programs are beginning to take seriously.